Great article that source, and it seems to agree with me ( I know...)

There is a version of this story circulating in popular media that frames it simply as a drug that grows back the teeth you lost as an adult. That framing is exciting but premature, and it is worth being precise about what the current trial is and is not. The Phase I trial is a safety study, not an efficacy trial. Its participants are healthy adult men missing at least one molar. The trial’s primary purpose is to determine whether the drug causes any adverse effects at human doses, not yet to demonstrate that a new tooth has grown in its place. The timeline for broader clinical use reflects this reality. The development timeline includes Phase I safety trials through 2025, Phase II efficacy trials in children with congenital tooth loss through 2027, and Phase III large-scale trials through 2029. Researchers aim for general availability by 2030. And even when the drug eventually reaches the market, the initial patient population will be children born without teeth due to genetic conditions, not adults who need a molar replaced.